ETANERCEPT RETENTION RATES IN PATIENTS WITH RHEUMATOID ARTHRITIS, ANKYLOSING SPONDYLITIS OR PSORIATIC ARTHRITIS

被引：1
|
作者：
Dongen, C. V. [1 ]
Kneepkens, E. [1 ]
Vogelzang, E. [1 ]
l'Ami, M. [1 ]
Krieckaert, C. [1 ]
van der Horst, I. [1 ,2 ]
Voskuyl, A. [2 ]
Nurmohamed, M. [1 ,3 ]
机构：
[1] Reade, Res & Educ, Amsterdam, Netherlands
[2] Vrije Univ Amsterdam Med Ctr, Rheumatol, Amsterdam, Netherlands
[3] Vrije Univ Amsterdam Med Ctr, Internal Med, Amsterdam, Netherlands
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2014年 / 73卷
关键词：
D O I：
10.1136/annrheumdis-2014-eular.5199
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB1043
引用
收藏
页码：1145 / 1145
页数：1
相关论文
共 50 条
  • [1] Risk: Benefit Profile of Etanercept in Elderly Patients with Rheumatoid Arthritis, Ankylosing Spondylitis or Psoriatic Arthritis
    Roy Fleischmann
    Imran Iqbal
    [J]. Drugs & Aging, 2007, 24 : 239 - 254
  • [2] Risk: Benefit profile of etanercept in elderly patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis
    Fleischmann, Roy
    Iqbal, Imran
    [J]. DRUGS & AGING, 2007, 24 (03) : 239 - 254
  • [3] Rates of cardiovascular events in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis treated with etanercept or placebo in clinical trials.
    Bathon, J.
    Fleischmann, R.
    Peloso, P.
    Chon, Y.
    Hooper, M.
    Lin, S-L
    [J]. ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S188 - S188
  • [4] The impact of etanercept on retinal microcirculation and vascular dysfunction in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
    Neumann, T.
    Knoll, K.
    Betge, S.
    Jung, C.
    Otto, G.
    Wolf, G.
    Saemann, A.
    [J]. ZEITSCHRIFT FUR RHEUMATOLOGIE, 2014, 73 : 12 - 12
  • [5] Biosimilar Etanercept Use in Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis: The RHUMADATA® Registry Experience
    Moura, Cristiano S.
    Choquette, Denis
    Coupal, Louis
    Bessette, Louis
    Bernatsky, Sasha
    [J]. ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [6] Interval prolongation of etanercept in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a randomized controlled trial
    Ruwaard, J.
    Ami, M. J. L'
    Kneepkens, E. L.
    Krieckaert, C. L. M.
    Nurmohamed, M. T.
    Hooijberg, F.
    van Kuijk, A. W. R.
    van Denderen, J. C.
    Burgemeister, L.
    Rispens, T.
    Boers, M.
    Wolbink, G. J.
    [J]. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2023, 52 (02) : 129 - 136
  • [7] Rates of serious infectious events and opportunistic infections in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis treated with etanercept or placebo in clinical trials
    Hamza, S.
    Chon, Y.
    Hooper, M.
    MacPeek, D.
    Lin, S.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 171 - 172
  • [8] Real-Life Retention Rates and Reasons for Switching of Biological DMARDs in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
    Bhushan, Vandana
    Lester, Susan
    Briggs, Liz
    Hijjawi, Raif
    Shanahan, E. Michael
    Pontifex, Eliza
    Ninan, Jem
    Hill, Catherine
    Cai, Fin
    Walker, Jennifer
    Goldblatt, Fiona
    Wechalekar, Mihir D.
    [J]. FRONTIERS IN MEDICINE, 2021, 8
  • [9] BIOLOGIC USE IN NHS PATIENTS WITH RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS
    Queen, Anton B.
    Siebert, Stefan
    [J]. RHEUMATOLOGY, 2016, 55 : 124 - 124
  • [10] Golimumab In the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
    Oldfield, Vicki
    Plosker, Greg L.
    [J]. BIODRUGS, 2009, 23 (02) : 125 - 135
12345